Muromonab-CD3

PreclinicalSmall molecule

BBarbara Ann Karmanos Cancer Institute

Muromonab-CD3 is one of 9 small molecule programs targeting Myocarditis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyocarditisActive, not recruiting

MyocarditisPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Myocarditis

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

—2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Medrol

3 4

Corlanor

Amgen

Preclinical

—5

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—6

Standard Medical Therapy

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 7

JYNNEOS

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

1 8

Drug Inducing Myocarditis

GGroupe Hospitalier Pitie-Salpetriere

Preclinical

1 9

Muromonab-CD3

BBarbara Ann Karmanos Cancer Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myocarditis2 trials

Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

Completed·MMayo Clinic·Phase 2·NCT00004482·40 enrolled

Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis

Completed·MMayo Clinic·N/A·NCT00027443·40 enrolled

Blood Disease1 trial

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00450983·1 enrolled

Melanoma1 trial

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00004022

Brain Tumors1 trial

Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors

Completed·UUniversity of Colorado, Denver·Phase 1·NCT00002572·10 enrolled

Metastatic Cancer1 trial

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

Unknown status·SSt. Vincent Medical Center - Los Angeles·Phase 1/2·NCT00002482

3 more indications

Kidney Cancer1 trial

Lymphocyte Therapy in Treating Patients With Kidney Cancer

Unknown status·NNational Cancer Institute (NCI)·Phase 2·NCT00002589·90 enrolled

Bone Marrow Transplantation1 trial

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005852

Oligodendroglioma1 trial

Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00004024·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Muromonab-CD3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Muromonab-CD3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Muromonab-CD3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Barbara Ann Karmanos Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBarbara Ann Karmanos Cancer Institute

Muromonab-CD3

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myocarditis2 trials

Blood Disease1 trial

Melanoma1 trial

Brain Tumors1 trial

Metastatic Cancer1 trial

Kidney Cancer1 trial

Bone Marrow Transplantation1 trial

Oligodendroglioma1 trial

References

Drug Info

Quick Facts

Related News